Navigation Links
GlycoCheck Announces Partnership in the United States with Vascular Health Sciences

Maastricht, The Netherlands (PRWEB) January 16, 2013

GlycoCheck B.V., a leading provider of imaging and measurement software of the endothelial glycocalyx layer, today announced a reseller partnership with U.S.-based Vascular Health Sciences.

Vascular Health Sciences will exclusively distribute GlycoCheck Vascular Health Monitor (VHM) in the United States. GlycoCheck VHM is a complete imaging solution for screening patients’ perfused boundary layer inside the blood vessels. The new technology measures and monitors changes in the glycocalyx layer non-invasively, accurately and in real time.

“We are pleased that Vascular Health Sciences has made a commitment to offer our GlycoCheck VHM solution to their customers throughout the United States,” said GlycoCheck CEO Pieter Goedhart.

GlycoCheck recently debuted in U.S. markets when Vascular Health Sciences attended the Age Management Medicine and Holistic Primary Care Conferences when doctors offered very favorable reviews of both GlycoCheck and Vascular Health Sciences’ all-natural artery health supplement, Arterosil.

“GlycoCheck provides a unique and novel technology to assess artery health in real time,” said Vascular Health Sciences Co-Founder and CEO Bob Long. “The more trials we conduct, both in the clinical setting and in a non-controlled conference setting, the more positive evidence we observe that proves Arterosil and Arterosil HP work. We’re thrilled to offer the benefits of this new technology to Health Care Practitioners and their patients.”

About GlycoCheck
GlycoCheck is a leading provider of imaging solutions based on an innovative measurement system of the Glycocalyx layer. GlycoCheck solutions facilitate the accurate, reliable and non-invasive selection, detection & monitoring of patients in primary care, intensive care, cardiology and internal medicine. To learn more about GlycoCheck, visit

About Vascular Health Sciences
Founded in 2010, Vascular Health Sciences explores technologies, develops products and disseminates information to increase awareness and promote the proper care of the endothelial glycocalyx. Vascular Health Sciences is committed to increasing awareness of the glycocalyx and its role in vascular health, and to providing products supporting the care of this essential system. For more information, visit

About Arterosil
Arterosil, a product of Vascular Health Sciences, is an all-natural health supplement focused on vascular health. It’s the only health supplement scientifically proven to support and maintain the glycocalyx, – the micro-thin gel-like lining that protects the heart, veins and arteries.* It’s also scientifically proven to optimize capillary architecture and increase micro-circulatory functionality.* Arterosil is available at, where monthly auto-ship options are available with free shipping, as well as 30-, 90- and 365-day supplies. Learn more at, or find Arterosil on Facebook and follow Arterosil on Twitter.

*FDA Disclaimer: These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure or prevent any disease.

Read the full story at

Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related biology technology :

1. Keryx Biopharmaceuticals, Inc. Announces Upcoming Poster Presentations of Zerenex™ (Ferric Citrate) at the Upcoming American Society of Nephrology Kidney Week 2011 Annual Meeting
2. VaxyGen Assay Services, LLC Announces Launch of Custom Bioassay Services and Operations
3. Sequenom Announces Participation at the Lazard Capital Markets 8th Annual Healthcare Conference
4. ACORN Research, LLC Announces Partnership with AdeptBio, LLC
5. GeoVax Labs, Inc. Announces Nine Month 2011 Financial Results
6. WuXi PharmaTech Announces Third-Quarter 2011 Results
7. Chimerix Announces Late-Breaking Poster Presentation at Kidney Week 2011 Annual Meeting
8. Spherix Announces Third Quarter Financial Results
9. Modern Mobility Aids, Inc. Announces November 30, 2011 Closing of Lumigene Acquisition
10. MedImmune Announces Winners of Its 6th Annual Global Abstract Competition
11. Nile Therapeutics Announces Top-Line Results in Clinical Trial Evaluating the Subcutaneous Infusion of Cenderitide, Meets Primary Endpoint
Post Your Comments:
(Date:11/24/2015)...  PDL BioPharma, Inc. (PDL) (NASDAQ: PDLI ) today ... and chief executive officer, will present at the 27 th ... New York City . The presentation will be ... at 9:30 a.m. EST. and go ... least 15 minutes prior to the presentation to allow for ...
(Date:11/24/2015)... (PRWEB) , ... November 24, 2015 , ... Whitehouse Laboratories ... Laboratory. The new stand-alone facility will be strictly dedicated to basic USP 61, ... and existing clients the chance to have complete chemistry and micro testing performed by ...
(Date:11/23/2015)... with a certain type of lung nodule visible on lung ... cancer than men with similar nodules, according to a new ... the Radiological Society of North America ... Lung nodules are small masses of tissue in the lungs ... appearance on CT. Solid nodules are dense, and they obscure ...
(Date:11/23/2015)... Nov. 23, 2015 China Cord Blood Corporation ... leading provider of cord blood collection, laboratory testing, hematopoietic ... announced its preliminary unaudited financial results for the second ... September 30, 2015. --> ... , Revenues for the second quarter of fiscal 2016 ...
Breaking Biology Technology:
(Date:11/12/2015)... Nov. 12, 2015  A golden retriever that stayed ... dystrophy (DMD) has provided a new lead for treating ... the Broad Institute of MIT and Harvard and the ... . Cell, pinpoints a protective ... the disease,s effects. The Boston Children,s lab of ...
(Date:11/10/2015)... , Nov. 10, 2015  In this ... the basis of product, type, application, disease ... in this report are consumables, services, software. ... are safety biomarkers, efficacy biomarkers, and validation ... report are diagnostics development, drug discovery and ...
(Date:11/4/2015)... York , November 4, 2015 ... a new market report published by Transparency Market Research "Home ... Growth, Trends and Forecast 2015 - 2022", the global home ... US$ 30.3 bn by 2022. The market is estimated ... forecast period from 2015 to 2022. Rising security needs ...
Breaking Biology News(10 mins):